# High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

> **NCT07559331** · PHASE3 · RECRUITING · sponsor: **Shandong University** · enrollment: 86 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** High-Dose Dexamethasone Combined with Orelabrutinib
- **DRUG:** High-Dose Dexamethasone Combined with Placebo

## Key facts

- **NCT ID:** NCT07559331
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2027-04-08
- **Final completion:** 2028-12-31
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559331, "High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07559331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*